Alpha-1 UK Support Group would like to congratulate our Trustee, Sandra Nestler-Parr, who today has delivered the keynote opening presentation at Takeda's President's Forum in Tokyo, Japan
Sandra delivered the keynote opening presentation on the topic "Putting patient centricity at work: An advocate' view". Takeda is a Top 10 global pharmaceutical company. With their recent acquisition of Shire, Takeda also acquired Aralast, an intravenous Alpha-1 augmentation therapy product available in the US. For Sandra to be invited to speak at this closed global leadership meeting is a great honour and recognition of her longstanding dedicated advocacy work in the rare disease patient community. It also offered a great platform to raise awareness of the unmet needs of the Alpha-1 patient community. In addition, I am very pleased to announce that Sandra will donate her generous honorarium for this speaker engagement to our patient charity. Please join me in thanking Sandra for this generous offer, particularly as she took annual leave from her day job in order to be able to travel all the way to Japan to give this presentation.